Background: Though most childhood cancer survivors experience late effects of treatment, we know little about parent preferences for late effects information during therapy, or how parents weigh late effects when making treatment decisions. Our objective was to explore how parents of children with cancer consider late effects in initial treatment decision making and during active cancer treatment.
INTRODUCTION
Because of iterative cooperative group trials, more than 80% of children diagnosed with cancer will become long-term survivors. 1 However, this cure comes with a cost, as the majority of childhood cancer survivors experience at least one late effect as a result of cancer or its treatment. 1, 2 Historically, clinicians have focused on providing late effects information, and educating survivors about their individual risk of long-term health issues, after treatment completion and in survivorship clinics. 3 Though several studies have shown that parents desire information about late effects in initial diagnosis and treatment conversations, [4] [5] [6] potential long-term health implications of treatment receive little attention in informed consent discussions. 7 Perhaps as a result, childhood cancer survivors and their parents report many unmet information needs about late effects of therapy, [8] [9] [10] and many parents feel suboptimally prepared for their children's survivorship. 11 There is little evidence on how best to provide information about potential late effects of therapy at the time of diagnosis.
Studies of survivors and their parents have indicated a preference for personalized, written late effects information. 8, 10, 12, 13 In disease-specific studies, survivors of lymphoma want information continuously offered from diagnosis through survivorship, and want information to be individualized, honest, and offered proactively by their providers prior to a patient's request. 12 However, studies about late effects information preferences have been conducted among survivors and their parents years after the initial diagnostic and treatment conversations, 8, 10, 12, 14 and perception of information received and desired may differ between diagnosis and survivorship. Furthermore, it is unclear whether and how parents consider late effects information when making treatment decisions. In this study, we interviewed parents of children actively receiving cancer therapy in the months immediately following their child's cancer diagnosis. We used a qualitative approach to explore parent preferences for information and communication about late effects of childhood cancer and to examine the role that concern for late effects plays in initial treatment decision making.
METHODS

Participants
Participants were recruited from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Parents of children within 1 year of cancer diagnosis who were actively receiving cancer-directed therapy were eligible. Pediatric oncology visit lists were screened regularly for potential candidates. English-speaking parents of children with cancer under 18 years of age at diagnosis on active treatment were eligible. Purposive sampling was used to ensure diversity of cancer diagnoses, prognoses, and participant sociodemographic factors. Patients' physicians were contacted to confirm eligibility and obtain permission to approach. Eligible parents were approached in-person by study staff at clinic visits or during inpatient stays. In total, 14 parents were approached, and 12 (86%) gave their consent to participate. One parent declined due to time constraints; one found the topic upsetting. 
Procedure
Individual semistructured interviews were conducted in-person by an interviewer trained in qualitative interview techniques. The interview guide included open-ended questions focusing on parents' recollection of late effects information provided in early treatment discussions and the role of late effects in their treatment decisions (Table 1) . Probing questions were asked for clarification or elaboration. Interviews were audio-recorded and transcribed verbatim. Continuous analysis was performed, and recruitment continued until thematic saturation was achieved.
Data analysis
All transcripts were coded independently by two authors (K.A.G. and A.D.) using standard comprehensive, directed thematic qualitative TA B L E 1 Interview questions. Parents were prompted to "Please think back to when you first received your child's diagnosis and had to make decisions about your child's treatment" analysis methods. A two-stage coding process was utilized for the analysis, with both prefigured and emergent codes. 15 Initial coding used questions from the interview guide as the framework for the prefigured coding structure. We used a framework orientation for the second phase of the analysis; a thematic framework was constructed from topics that emerged from the data, and this framework was then applied to all transcripts. 16 
RESULTS
Characteristics of participating parents and their children are shown in Table 2 . Main themes elicited included desire for information about late effects, late effects worries, and late effects as a consideration in treatment decision making. Quotes are annotated with parent number and gender (Parent X, M/F).
Parent late effect information preferences
All parents wanted to learn about their child's risks of late effects and considered this information important (Table 3) . One parent com- felt too inundated with information at diagnosis to consider late effects and instead felt that they require a separate, later conversation:
It's hard enough to realize that she has to go through this for 2 years, and this is what's happening, this is what could happen to her body now, and then… it seems so overwhelming to think about down the road… it's a whole other diagnosis to think about what could happen down the road. (Parent 4, F)
Several parents expressed ambivalence, simultaneously wanting information while at the same time finding information daunting. "For some people, more information is better. For some people, more information is overwhelming. And for someone like me, both of those things are true" (Parent 10, F).
Parents especially wanted information about actionable late effects, which they could try to prevent or ameliorate. "I wanna do whatever I can to protect my child… [don't] tell me after the fact" (Parent 10, F). They also wanted to know what was most likely to occur to their child, "They gave us these sheets of paper that had 'likely,' 'unlikely,' and 'very unlikely' side effects; and to be quite frank, I kind of looked at the 'likely,' I didn't really pay much attention to the rest…" (Parent 7, M). Some parents also expressed that it would be helpful to understand how the combination of therapies impacted their child's likelihood of late effects, instead of learning separately about the late effects associated with each individual treatment or chemotherapeutic. Many parents were satisfied with the quantity and quality of late effects information provided by their child's medical team. "My wife and I went through all the paperwork that they gave us, and then, of course there was a lengthy discussion about it, and then there was more discussion, then we signed paperwork, there was more discussion, so I felt like we were very well informed" (Parent 2, M). However, even those who felt they received high-quality information found the presentation of information quite daunting, and many still had unanswered questions about likelihoods of specific late effects, or about the risks associated with combinations of treatments. "I felt that I had enough information… but fertility options weren't discussed before" we haven't given enough thought to the long-term effects, but at the same time I feel like it doesn't impact your decision, because she has to get the treatment and you just have to hope for the best" (Parent 9, F).
TA B L E 3 Parent late effects information preferences
Role of late effects in treatment decision making
In describing the process of making treatment decisions, some parents commented on information presentation formats, or their doctor's approach to decision making, and how different styles impacted their decision-making process. One parent was appreciative of the way her child's physician engaged her family in decision making:
He never told us what he would do, and he thought it was so important for our family to make the choice on our own… I really admired him for that… the easy way out is just to have your doctor say, 'this is what you should do,' but he knew that the choice was life-altering, for a family and a person, and he honestly educated us on each one. (Parent 6, F)
Many parents found the pages of potential acute and long-term side effects described in informed consent documents to be comprehensive 
DISCUSSION
While informed consent documents for pediatric cancer treatment contain information on potential late effects, the majority of late effects education has typically occurred after treatment completion, during long-term follow-up care. 3, 17, 18 This approach has clear meritssurvivorship is when late effects screening is required, and when most late effects occur. This timing also allows education of survivors who may have been too young to participate in discussions at diagnosis. 18 However, this approach neglects the role of late effects information in initial treatment decision making. Parents in this study valued late effects information from the time of diagnosis, because it helped them to feel prepared for what is ahead and informed the decisions they made about their children's care.
Parents of seriously ill children view informed medical decision making to be a primary component of good parenting. 19, 20 Our findings suggest that we should consider conveying more information about possible late effects in an upfront setting to meet parental desire for information and to allow parents to engage in shared decisions about treatment. Waiting to fully discuss potential late effects of treatment until completion of therapy and survivorship may not meet parent information needs, and may hinder informed decision making.
Providing upfront information about potential late effects of childhood cancer therapy poses many challenges. Early diagnostic and treatment conversations, or Day One talks, are emotional conversations during which a child's diagnosis, prognosis, and proposed treatment are discussed, leaving little time or emotional capacity to also review potential late effects. 4, 21, 22 Furthermore, the risks of late effects can be challenging to estimate, let alone convey to families.
Many providers are uncomfortable in providing information about late effects of therapy even after treatment completion as they fear taking away hope. 23 Adult oncology providers worry that information about potential late effects of cancer and its treatment will be emotionally upsetting to cancer survivors as it "could have a negative impact on psychological adjustment to life as a cancer survivor and may actually increase the experience of late effects through autosuggestion." 23 These concerns are likely magnified in the setting of heightened emotions at diagnosis. However, survivors of childhood cancer with unmet late effects information needs are more likely to experience depression, anxiety and inferior mental and physical health related quality of life, 8, 9, 24 and lack of information does not decrease late effect worries, 10, 25 underscoring the potential importance of this information to psychological health.
Disclosure of information about late effects has parallels to conversations about prognosis, where physicians similarly worry about causing distress and loss of hope. Research on prognostic disclosure suggests that providing information, even if upsetting, is critically important to parents of children with cancer and does not diminish hope. 26, 27 While a subset of parents of children with cancer find prognostic information quite upsetting, parents who are upset by the information find it equally valuable and still desire detailed information. 27, 28 In fact, omission of prognostic information can impede the therapeutic alliance between parents and providers, and negatively impact parental decision making. 28 Just as understanding of prognosis has been shown to result in different treatment choices, 29 our findings suggest that parental understanding of late effects risks may impact treatment decision making. Therefore, even if parents find late effects information upsetting, many still need and desire this information.
A child's diagnosis, prognosis, and the availability of treatment options may all affect the type and amount of information desired by parents, and whether parents consider late effects when making treatment decisions. The role of these factors in parent information preferences was not explored in this small qualitative study. In our practice, we typically review the late effects information on informed consent documents with parents, focusing on those late effects we think we might be able to prevent, those we need to monitor for, and those we think parents should be prepared for. Further investigation is required to understand how best to provide late effects information in a way that meets individual parent information needs and offers realistic estimations of risk, while simultaneously supporting hope. However, parents in our study offered some guidance. First, parents wanted to be offered information about late effects. Second, they wanted their own information needs and preferences to guide discussions and desired the opportunity to defer detailed discussions. We would add that clin-
icians must consider what information is essential for decision making and informed consent, such that some information may need to be shared regardless of a parent's desire to avoid it. But when information can be deferred for the relatively few parents who wish to do so, clinicians can openly discuss this decision and make a commitment to readdress late effects in the future. Finally, many parents commented on the lengthy "paperwork" provided which typically lists late effects by chemotherapeutic agent, and found it difficult to decipher the implications of the comprehensive treatment regimen. New ways of conveying a more integrated view of a child's future in both our verbal and written communication are needed.
Our study had several limitations. We collected perspectives from 12 parents at a single institution, posing concerns about the generalizability of our findings. However, many children and families receive cancer care at pediatric cancer centers like ours, and through purposive sampling we collected varied parent perspectives. Furthermore, as more than 50% of children with cancer are treated on a clinical trial, 30,31 many parents receive similar informed consent documents that outline potential late effects. We interviewed parents in the months after initial diagnostic and treatment conversations, making it possible that important elements of the communication process were forgotten during the time that elapsed between the day 1 conversation and our interviews. Despite the time lapse, many parents recalled aspects of these conversations in detail, and this timing was more proximal to treatment discussions than prior studies that have queried parents and survivors years after treatment completion, and after some survivors have experienced late effects. Lastly, the child's voice is missing from this study. We interviewed parents of children who were less 
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